OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Articolo
Data di Pubblicazione:
2022
Abstract:
Limited data about use of biosimilars (BIOs) are available in children with JIA. This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars (BIOs), in children with JIA, in a real-world setting.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
JIA; TNF-inhibitors; adalimumab; anti-TNF; biologics; biosimilar; children; efficacy; etanercept; safety; Adalimumab; Child; Cohort Studies; Drug Substitution; Etanercept; Female; Glass; Humans; Prospective Studies; Treatment Outcome; Antirheumatic Agents; Arthritis, Juvenile; Biosimilar Pharmaceuticals
Elenco autori:
Maccora, Ilaria; Lombardi, Niccolò; Crescioli, Giada; Bettiol, Alessandra; Bonaiuti, Roberto; Pagnini, Ilaria; Maniscalco, Valerio; Marrani, Edoardo; Mastrolia, Maria Vincenza; Ravaldi, Claudia; Consolini, Rita; Cattalini, Marco; Vannacci, Alfredo; Simonini, Gabriele
Link alla scheda completa:
Link al Full Text:
Pubblicato in: